For this purpose, we examined whether SIL exerts its cardioprotective effects through the modulation of HIF-1α-mediated glycolysis, with the goal of identifying novel therapeutic targets for post-MI heart failure management. The gene discussed is HIF1A; the disease is myocardial infarction.